Thank you for the question, honourable member.
All you have to do is take a look at what's transpired since 2018 when the PMPRB guidelines were initially put out, from the perspective of clinical trials and from the perspective of new drug launches in Canada. Of 34 drug launches globally, 21 of those drugs have not been launched in Canada. These drugs represent rare disease oncology products. Beyond that, honourable member, if you take a look at the clinicaltrials.gov website, where all clinical trials have to register—it's a federal website—the number of clinical trials in Canada has dropped significantly since these guidelines were put out. All you need to do is take a look at what's transpired since 2018, and the data is there.